Literature DB >> 16938543

Inhibition of inflammatory responses by leukocyte Ig-like receptors.

Howard R Katz1.   

Abstract

The immune system must effectively regulate the balance between beneficial and detrimental inflammation. This process is achieved in part through cell surface receptors that rapidly integrate activating and inhibitory signals. The inhibitory members of the leukocyte Ig-like receptor (LILR) family, termed LILRBs, are broadly distributed among cell populations in the immune system and potently counterregulate cell activation induced by stimuli of innate and adaptive immune responses. Studies in mice and humans indicate that LILRBs appreciably downregulate harmful inflammatory responses induced by microbial, allergic, and cytotoxic mechanisms. Hence, the LILRBs likely play significant roles in regulating the incidence and severity of many inflammatory diseases, making them potential targets for therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16938543     DOI: 10.1016/S0065-2776(06)91007-4

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  15 in total

Review 1.  LILRB receptor-mediated regulation of myeloid cell maturation and function.

Authors:  William van der Touw; Hui-Ming Chen; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Immunol Immunother       Date:  2017-06-21       Impact factor: 6.968

Review 2.  Leukocyte immunoglobulin-like receptors in human diseases: an overview of their distribution, function, and potential application for immunotherapies.

Authors:  Jilu Zhang; Sunny Mai; Hui-Ming Chen; Kyeongah Kang; Xian Chang Li; Shu-Hsia Chen; Ping-Ying Pan
Journal:  J Leukoc Biol       Date:  2017-03-28       Impact factor: 4.962

Review 3.  Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells.

Authors:  Wei Cao; Laura Bover
Journal:  Immunol Rev       Date:  2010-03       Impact factor: 12.988

4.  Brucella CβG induces a dual pro- and anti-inflammatory response leading to a transient neutrophil recruitment.

Authors:  Clara Degos; Aurélie Gagnaire; Romain Banchereau; Ignacio Moriyón; Jean-Pierre Gorvel
Journal:  Virulence       Date:  2015       Impact factor: 5.882

Review 5.  New Targets for Antiviral Therapy: Inhibitory Receptors and Immune Checkpoints on Myeloid Cells.

Authors:  Yanni Liu; Paul Nicklin; Yuan He
Journal:  Viruses       Date:  2022-05-25       Impact factor: 5.818

Review 6.  HLA-G: a human pregnancy-related immunomodulator.

Authors:  Joan S Hunt; Daudi L Langat
Journal:  Curr Opin Pharmacol       Date:  2009-06-29       Impact factor: 5.547

Review 7.  Phagocytosis checkpoints as new targets for cancer immunotherapy.

Authors:  Mingye Feng; Wen Jiang; Betty Y S Kim; Cheng Cheng Zhang; Yang-Xin Fu; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2019-08-28       Impact factor: 60.716

8.  Leukocyte immunoglobulin-like receptor B4 regulates key signalling molecules involved in FcγRI-mediated clathrin-dependent endocytosis and phagocytosis.

Authors:  Mijeong Park; Mark J Raftery; Paul S Thomas; Carolyn L Geczy; Katherine Bryant; Nicodemus Tedla
Journal:  Sci Rep       Date:  2016-10-11       Impact factor: 4.379

Review 9.  Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors.

Authors:  Xunlei Kang; Jaehyup Kim; Mi Deng; Samuel John; Heyu Chen; Guojin Wu; Hiep Phan; Cheng Cheng Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

10.  Common and rare variants associating with serum levels of creatine kinase and lactate dehydrogenase.

Authors:  Ragnar P Kristjansson; Asmundur Oddsson; Hannes Helgason; Gardar Sveinbjornsson; Gudny A Arnadottir; Brynjar O Jensson; Aslaug Jonasdottir; Adalbjorg Jonasdottir; G Bragi Walters; Gerald Sulem; Arna Oskarsdottir; Stefania Benonisdottir; Olafur B Davidsson; Gisli Masson; Olafur Th Magnusson; Hilma Holm; Olof Sigurdardottir; Ingileif Jonsdottir; Gudmundur I Eyjolfsson; Isleifur Olafsson; Daniel F Gudbjartsson; Unnur Thorsteinsdottir; Patrick Sulem; Kari Stefansson
Journal:  Nat Commun       Date:  2016-02-03       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.